Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) Director Joshua S. Boger sold 5,200 shares of Vertex Pharmaceuticals stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $88.00, for a total transaction of $457,600.00. Following the completion of the transaction, the director now directly owns 338,895 shares of the company’s stock, valued at approximately $29,822,760. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.56% during mid-day trading on Friday, hitting $90.88. 1,053,292 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $99.74. The stock has a 50-day moving average of $93.37 and a 200-day moving average of $78.50. The company’s market cap is $21.637 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Tuesday, July 29th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was down 55.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.89 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, July 31st. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Finally, analysts at Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $102.82.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.